VBL2021Logo_Dark.jpg
VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting
October 12, 2023 09:00 ET | VBL Therapeutics
Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of...
VBL2021Logo_Dark.jpg
VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting
October 04, 2023 08:00 ET | VBL Therapeutics
MODI’IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), reminds its shareholders to vote in favor of the previously announced proposed merger (the...
VBL2021Logo_Dark.jpg
VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC
September 06, 2023 08:00 ET | VBL Therapeutics
Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI’IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE...
VBL2021Logo_Dark.jpg
VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 14, 2023 08:00 ET | VBL Therapeutics
Merger with Notable expected to close in late September or October, subject to VBL’s S-4 registration statement being declared effective and shareholder approval $24.3 million in cash and cash...
VBL2021Logo_Dark.jpg
VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023 16:01 ET | VBL Therapeutics
MODI’IN, Israel and NEW YORK, May 15, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced financial results for the first quarter ended March 31, 2023, and provided a...
VBL2021Logo_Dark.jpg
VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
March 14, 2023 08:00 ET | VBL Therapeutics
MODIIN, Israel and NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), today announced financial results for the fiscal year ended December 31, 2022, and provided a...
VBL2021Logo_Dark.jpg
VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
March 09, 2023 08:00 ET | VBL Therapeutics
MODIIN, Israel and NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that it has closed on the previously announced sale of its manufacturing facility in...
VBL2021Logo_Dark.jpg
VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement
February 23, 2023 07:00 ET | VBL Therapeutics
Merger will create Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations selected through Notable’s proprietary Predictive Precision...
VBL2021Logo_Dark.jpg
VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
February 16, 2023 08:00 ET | VBL Therapeutics
MODIIN, Israel and NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, announced...
VBL2021Logo_Dark.jpg
VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022 16:05 ET | VBL Therapeutics
TEL AVIV, Israel and NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing targeted medicines for immune-inflammatory...